KRAS and Patent ductus arteriosus: However, our whole tumor gene signatures furthermore pointed at an important role of MEKi-induced tumor cell death in this respect, in particular in the mutant K-ras driven PDA model, in that MEKi single agent treatment already induced a pro-inflammatory gene signature associated with IFN pathway activation.